What Is Eczema?
Atopic dermatitis — the full clinical name for what most people call eczema — is a chronic, relapsing inflammatory skin condition characterized by intense itch, dryness, and compromised barrier function. The word "atopic" refers to a genetic tendency toward allergic conditions, which is why eczema, asthma, allergic rhinitis, and food allergies so often travel together in the same individuals. This cluster is called the "atopic march."
But the mechanism that drives eczema flares is not primarily an immune overreaction to allergens. The primary defect is structural: a barrier that cannot hold water in or keep irritants out. Once you understand that distinction, the logic of every evidence-backed treatment intervention becomes much clearer.
Eczema presents differently across skin tones and life stages. In infants, it typically appears on the cheeks, scalp, and extensor surfaces of the arms and legs. In older children and adults, the flexural creases — the inner elbows, behind the knees, the wrists, ankles — are the most common sites. On darker skin tones, eczema often presents as hyperpigmentation or lichenification (skin thickening) rather than the classic red, weeping rash more commonly depicted in medical literature.
The Role of the Skin Barrier in Eczema
The most important genetic discovery in eczema research was the identification, in 2006, of loss-of-function mutations in the filaggrin gene. Filaggrin is a protein essential for forming the protein scaffold inside corneocytes — the dead, flattened cells that make up the outermost skin layer. When filaggrin is deficient or absent, the skin cells cannot bind together properly, the lipid matrix is disorganized, and the barrier becomes permeable.
A permeable barrier means two things happen simultaneously. Water evaporates through the skin more rapidly — transepidermal water loss (TEWL) rises significantly — and environmental antigens including house dust mite proteins, pet dander, and bacterial toxins from Staphylococcus aureus can penetrate the compromised surface and trigger immune activation. In eczematous skin, colonization by S. aureus is found in over 90% of patients during flares, compared to roughly 30% of healthy skin. The bacteria release proteases and toxins that further degrade barrier lipids, amplifying the inflammatory response.
This is the barrier-immune-barrier feedback loop: compromised barrier allows allergen penetration, which triggers Th2-dominant immune activation, which drives inflammation and itch, which causes scratching, which mechanically destroys more barrier, which allows more allergen penetration. Treating only the itch — without rebuilding the barrier — addresses a symptom while the root cause continues to cycle.
Eczema Triggers: What They Actually Do
Triggers do not cause eczema — they stress a barrier that is already structurally compromised and tip it into a flare. Understanding this reframes how to approach trigger management.
The most consistently documented triggers across clinical studies include:
- Harsh cleansers and soaps. Surfactants — particularly sodium lauryl sulfate (SLS) — strip ceramides from the skin surface, elevate skin pH above its optimal 4.5–5.5 range, and activate serine proteases that degrade barrier proteins. Switching to a lipid-replenishing, pH-balanced cleanser is one of the highest-impact changes for eczema patients.
- Temperature extremes and sweat. Heat increases histamine release and amplifies itch. Cold, dry air accelerates TEWL by thinning the protective lipid film. Sweating exposes the skin to salt and proteins that irritate already-inflamed tissue.
- Fragrances and preservatives. Fragrance is the most common contact allergen in the eczema population. Products labeled "natural" or "botanical" are not automatically safer — essential oils including linalool, limonene, and citral are among the most frequent sensitizers. Preservatives such as methylisothiazolinone (MI) are also well-documented triggers.
- Psychological stress. Stress elevates cortisol and activates the hypothalamic-pituitary-adrenal axis, which increases mast cell degranulation and histamine release. Clinically, patients consistently report flares in the days following high-stress events, not during them — the immune response lags.
- Sleep deprivation. Skin barrier repair peaks between 11 p.m. and 4 a.m. as growth hormone levels rise. Shortened or disrupted sleep measurably increases TEWL and impairs overnight barrier recovery.
The Evidence-Backed Treatment Approach
Modern eczema management rests on three concurrent pillars: barrier repair, anti-inflammatory intervention, and trigger reduction. These are not sequential steps — they work best when applied together.
Barrier repair as a treatment, not just maintenance. Multiple randomized controlled trials have demonstrated that proactive, consistent use of emollients — applied twice daily or more — reduces flare frequency, decreases corticosteroid use, and lowers the risk of secondary infection. The most effective emollient formulations contain ceramides, cholesterol, and free fatty acids in the ratios found in healthy skin (approximately 3:1:1). Formulations that contain only humectants or only occlusive agents show weaker results.
Topical corticosteroids (TCS) for active flares. TCS remain the first-line anti-inflammatory treatment and have a strong safety record when used at the correct potency and frequency. The appropriate approach is: use TCS to clear active inflammation, then step down to an emollient-only maintenance regimen as quickly as possible. Corticosteroid phobia — driven by misunderstanding of skin atrophy risk — is a documented cause of undertreated eczema. Used correctly, low-to-mid potency TCS do not cause clinically significant atrophy.
Topical calcineurin inhibitors (TCI) for sensitive areas. Tacrolimus (Protopic) and pimecrolimus (Elidel) are non-steroidal anti-inflammatory options suitable for the face, neck, and skin folds where corticosteroid use is more constrained. They inhibit T-cell activation without affecting skin thickness and are now recommended for long-term maintenance use in sensitive sites.
Dupilumab for moderate-to-severe disease. Dupilumab is a biologic therapy that blocks both IL-4 and IL-13 signaling — the primary cytokines driving Th2-dominant inflammation in eczema. Phase III trial data shows 50–70% reductions in disease severity scores and dramatic improvements in itch and sleep quality. It does not suppress the immune system broadly and has a well-characterized safety profile. For patients with moderate-to-severe disease inadequately controlled by topicals, it represents a significant treatment advance.
Proactive therapy. Rather than waiting for a flare and reacting, proactive therapy applies a low-potency topical anti-inflammatory 2–3 times per week to areas that historically flare, even when the skin appears clear. This approach reduces flare frequency by approximately 50% in patients who follow it consistently. The underlying rationale is that subclinical inflammation persists in these areas even between visible flares.
Product Approach for Eczema-Prone Skin
The product selection framework for eczema is built around a short, intentional ingredient list rather than a long routine. More products means more potential irritants, more fragrance exposure, and more opportunities to disrupt a compromised barrier.
The non-negotiables for an eczema-appropriate routine are: a pH-balanced cleanser free of SLS, SLES, and fragrance; a ceramide-dominant emollient applied within three minutes of cleansing (the "soak and seal" method); and sun protection with a mineral-based sunscreen (zinc oxide or titanium dioxide) that avoids chemical UV filters, which can be irritating on sensitive skin.
